PLAINSBORO, N.J., Feb. 21, 2018 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the following healthcare conferences in March:
- On Monday, March 5, 2018 at 4:35 p.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, FL. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.
- On Tuesday, March 13, 2018 at 8:30 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Barclays Global Healthcare Conference in Miami Beach, FL. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.
- On Wednesday, March 21, 2018 at 10:20 a.m. ET, Dan Reuvers, corporate vice president and president of Codman Specialty Surgical, will present at the Oppenheimer 28th Annual Healthcare Conference in New York City.
About Integra
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
[email protected]
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
[email protected]


SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises
OpenAI Restricts Astra AI Over Cyberattack Risks
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 



